Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Next Previous
X
Search
Trial Profile

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NGM 621 (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CATALINA
  • Sponsors NGM Biopharmaceuticals

    • Most Recent Events

    • 13 Jun 2023 Number of treatment arms have been increased from 3 to 4 by the addition of Sham Comparator: Sham Group D (every 8 weeks) arm.
    • 03 Nov 2022 Results from post-hoc analyses of the study published in the NGM Biopharmaceuticals Media Release.
    • 03 Nov 2022 According to a NGM Biopharmaceuticals media release, findings from post-hoc analyses of the study were presented at The Retina Society Annual Scientific Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top